Article ; Online: IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
2023 Volume 175, Page(s) 132–136
Abstract: Objective: To. determine the impact of 5-α reductase inhibitors or α-blockers on IsoPSA performance for the detection of actionable prostate cancer.: Materials and methods: This is a secondary analysis of data from an institutional review board ... ...
Abstract | Objective: To. determine the impact of 5-α reductase inhibitors or α-blockers on IsoPSA performance for the detection of actionable prostate cancer. Materials and methods: This is a secondary analysis of data from an institutional review board approved, prospective, multicenter(8-sites) study evaluating IsoPSA in men ≥ 50 years of age with a total PSA ≥ 4 ng/mL with planned prostate biopsy who met previously described inclusion and exclusion criteria. Analytic groups included (i)all subjects, (ii-iii)+/- 5-ARI use, (iv-v)+/- α-blocker use. The performance characteristics of IsoPSA in these groups were assessed by ROC curve, sensitivity, and specificity (SP) analysis. Results: A total of 1385 men were recruited with 888 men included in final analysis. Actionable prostate cancer, defined as GG2+, was identified in a total of 316 patients with 40 and 217 patients reporting 5-ARI and α-blocker use respectively. Sensitivity to detect both prostate cancer and actionable cancer was similar between patient subsets (P >.05). SP was similar between patients regardless of 5-ARI(P >.05). Increased SP was noted in patients on α-blockers(GG1+: No-α-blocker: 0.360 vs α-blocker: 0.529, P <.05; GG2+: No-α-blocker: 0.40 vs α-blocker: 0.61, P <.05). ROC analysis demonstrates that IsoPSA performance is unaffected by 5-ARI or α-blocker use for prostate cancer and actionable cancer (GG2+) detection. Conclusion: The performance of IsoPSA for detecting any prostate cancer and clinically actionable prostate cancer is unaffected by commonly used medications (5-ARI and α-blockers) for symptoms of benign prostatic hyperplasia. |
---|---|
MeSH term(s) | Male ; Humans ; 5-alpha Reductase Inhibitors/therapeutic use ; Prostate-Specific Antigen ; Prospective Studies ; Prostatic Neoplasms/pathology ; Prostatic Hyperplasia/complications ; Adrenergic alpha-Antagonists/therapeutic use |
Chemical Substances | 5-alpha Reductase Inhibitors ; Prostate-Specific Antigen (EC 3.4.21.77) ; Adrenergic alpha-Antagonists |
Language | English |
Publishing date | 2023-02-16 |
Publishing country | United States |
Document type | Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 192062-5 |
ISSN | 1527-9995 ; 0090-4295 |
ISSN (online) | 1527-9995 |
ISSN | 0090-4295 |
DOI | 10.1016/j.urology.2023.01.037 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1142: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 275: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.